VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.
Viventia Biotech Inc, under license from the University of Zurich, is developing VB4-845, comprising a Pseudomonas exotoxin fused to an anti-epithelial cell adhesion molecule single-chain antibody fragment, for the potential treatment of head and neck cancer (intratumoral) and bladder cancer (intravesical). VB4-845 is currently undergoing phase II and III clinical trials in patients with head and neck squamous cell carcinomas, as well as phase II clinical trials for the treatment of superficial transitional cell carcinoma of the bladder.
Biggers
Kristen
K
West Virginia University School of Medicine, Robert C Byrd Health Sciences Center, Morgantown, WV 26506-9100, USA.
Scheinfeld
Noah
N
D000906:Antibodies / Q000378:metabolism / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004353:Drug Evaluation, Preclinical; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D000922:Immunotoxins / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013329:Structure-Activity Relationship; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000906:Antibodies; D000970:Antineoplastic Agents; D000922:Immunotoxins; D011994:Recombinant Proteins